US FDA gives Ziopharm go-ahead to test oral cancer drug
This article was originally published in Scrip
Executive Summary
Cancer drug maker Ziopharm Oncology said the US FDA accepted the New York firm's investigational new drug application (IND) to test oral dosing of palifosfamide (ZIO-201), a novel DNA cross-linker, which is in class with bendamustine, ifosfamide and cyclophosphamide.